In summary, this study demonstrated that increased HRG levels after tPA treatment can regulate neutrophil immune activity and inhibit neutrophil infiltration and excessive immune activation, thereby reducing the risk of tPA-related HT and extending the thrombolytic time window. The gene discussed is PLAT; the disease is hematocrit.